Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amcad BiomedROCO:4188 -0.32%53 Current Ratio is 22.62 as of Dec. 2025, which is 58% above its 10-year median of 14.34. GuruFocus rates ROCO:4188 with a GF Score™ of 53/100 and a GF Value™ of NT$9.10 (Fairly Valued). The stock has 4 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Amcad Biomed ranks better than 98.59% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Amcad Biomed's current ratio for the quarter that ended in Dec. 2025 was 22.62.
Amcad Biomed has a current ratio of 22.62. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Amcad Biomed's Current Ratio or its related term are showing as below:
ROCO:4188'
s Current Ratio Range Over the Past 10 Years
Min: 7.38 Med: 14.34 Max: 31.77
Current: 22.62
During the past 13 years, Amcad Biomed's highest Current Ratio was 31.77. The lowest was 7.38. And the median was 14.34.
ROCO:4188's Current Ratio is ranked better than 98.59% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 2.49
vs ROCO:4188: 22.62
Amcad Biomed (ROCO:4188) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Amcad Biomed Current Ratio Related Terms
Amcad Biomed Current Ratio Historical Data
* Premium members only.
The historical data trend for Amcad Biomed's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4188 vs ABT, SYK, MDT: Current Ratio Comparison
For the Medical Devices subindustry, Amcad Biomed's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amcad Biomed Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Amcad Biomed's Current Ratio distribution charts can be found below:
* The bar in red indicates where Amcad Biomed's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amcad Biomed (ROCO:4188) has a Current Ratio of 22.62 as of Dec. 2025. This is 58% above median its historical median of 14.34. Over the past decade, Amcad Biomed's Current Ratio has ranged from 7.38 to 31.77. According to the industry distribution chart, Amcad Biomed ranks #12 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 1.4%.
Is Amcad Biomed's Current Ratio too high?
Amcad Biomed's current Current Ratio of 22.62 is 58% above median its 10-year median of 14.34. Over the past 10 years, this metric has ranged from a low of 7.38 to a high of 31.77. The Medical Devices & Instruments industry median Current Ratio is 2.49. Amcad Biomed's value of 22.62 is 808.4% above this industry median. Based on the distribution chart, Amcad Biomed ranks #12 out of 852 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Amcad Biomed has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amcad Biomed's Current Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Amcad Biomed ranks #12 out of 852 companies for Current Ratio. This places Amcad Biomed in the top 1% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.49. Amcad Biomed's value of 22.62 is 808.4% above this benchmark. Historically, Amcad Biomed's own Current Ratio has ranged from 7.38 to 31.77 over the past decade. While the company's 10-year median is 14.34 vs. the industry median of 2.49, Amcad Biomed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.49, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amcad Biomed's current Current Ratio of 22.62 is 808.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amcad Biomed's current Current Ratio is 22.62, which is 58% above median its own 10-year median of 14.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amcad Biomed stock overvalued right now?
Based on GuruFocus' analysis, Amcad Biomed (ROCO:4188) is currently considered Fairly Valued. The stock's GF Value™ is NT$9.10, compared to a current price of NT$9.45 — trading 3.8% above its estimated fair value. The current Current Ratio is 22.62, which is 58% above median its 10-year median of 14.34 and 808.4% above the Medical Devices & Instruments industry median of 2.49. Amcad Biomed's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Amcad Biomed (ROCO:4188), the current Current Ratio is 22.62 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amcad Biomed (ROCO:4188) Overvalued in 2026?
Based on GuruFocus' analysis, Amcad Biomed stock appears to be overvalued.
The current stock price of NT$9.45 is trading 3.8% above its estimated GF Value™ of NT$9.10.
GuruFocus considers Amcad Biomed to be Fairly Valued.
Key valuation signals for ROCO:4188:
Current Ratio: 22.62 (58% above median its 10-year median of 14.34)
GF Value™: NT$9.10 vs. price of NT$9.45 (3.8% above fair value)
Industry Position: 808.4% above the Medical Devices & Instruments median (#12 of 852)
No single metric tells the full story. See the ROCO:4188 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, AmCAD-UV, AmCAD and AmCAD-UO. Geographically, the company generates revenue from Taiwan, China, Europe, Asia (excluding Taiwan and China), and other countries, out of which the majority of the revenue is generated from Taiwan. The company has two segments: the Medical Diagnostic Software segment, which is responsible for the development and sales of smart medical imaging diagnostic software devices, and the Precision Medical Equipment segment, which is responsible for research, development, manufacturing, and sales of high-end ultrasonic probes. The company generates the majority of its revenue from the Precision Medical Equipment segment.
53GF Score
Get the complete analysis for ROCO:4188
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4188 has been successfully added to your 
